https://www.nabtrade.com.au/investor/insights/latest-news/news/2018/01/4_promising_biotechs
immutep is at the forefront of the approach of harnessing the immune system’s abilities as the future frontier of cancer treatment, with a particular focus on combination therapies. Major global pharmaceutical companies are backing LAG-3 as a meaningful therapeutic target, leaving IMM nicely positioned as the intellectual property owner.
And still we wait for this to reflect on the SH price!
Promising biotech 2018
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.3¢ |
Change
0.008(2.63%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 29.0¢ | $142.8K | 490.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 24171 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 135412 | 18 |
View Market Depth
| Last trade - 10.18am 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
